Accéder au contenu
Merck

Lipidomics Magazine Volume 3

Lipodomics Volume 3 brochure cover

Leading Research From Wiley

  • Angewandte Chemie International Edition
  • small
  • Advanced Materials
  • WIREs Nanomedicine and Nanobiotechnology
  • Journal of Biomedical Materials Research

Messenger RNA (mRNA), a single-stranded RNA involved in protein synthesis, has emerged as a promising therapeutic strategy in the treatment and prevention of diseases and disorders. mRNA therapies have the potential to transform the standard of care for many different diseases and actualize personalized medicine. During the COVID-19 pandemic, the success of several mRNA vaccines was instrumental in developing immunity against COVID-19 in addition to elucidating a deeper understanding of the disease itself. As a result, the last few years have led to a renewed and vested interest in mRNA therapies in both society and in the greater medical and scientific communities.


Download Free Lipidomics eBook

Fields indicated by an * are required.


Content Overview

Page 4
Editorial

Page 5
Graphic: Lipid Nanoparticle Delivery of mRNA Therapies

Page 6
Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs
Fenton O.S., Kauffman K.J., McClellan R.L., et al.

Page 7
Subcellular Delivery of Lipid Nanoparticles to Endoplasmic Reticulum and Mitochondria
Shi Y., Luo Z., You J.

Page 10
Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH
Hajj K.A., Ball R.L., Deluty S.B., et al.

Page 11
Nanoscale Platforms for Messenger RNA Delivery
Li B., Zhang X., Dong Y.

Page 13
Anionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System
Pattipeiluhu R., Arias-Alpizar G., Basha G., et al.

Page 15
Lipid-Based Nucleic Acid Therapeutics with In Vivo Efficacyy
Sufian M.A., Ilies M.A.

Page 19
Rational Design of Anti-inflammatory Lipid Nanoparticles for mRNA Delivery
Zhang H., Han X., Alameh M.G., et al.

Connectez-vous pour continuer

Pour continuer à lire, veuillez vous connecter à votre compte ou en créer un.

Vous n'avez pas de compte ?